AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05740176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Cervical Discectomy and Fusion
Description: Anterior cervical discectomy is a surgical procedure that was developed to treat damaged cervical discs by relieving pressure on the nerve roots or on the spinal cord by removing the ruptured disc. The operation is performed by reaching the cervical spine through a small incision in the front of the neck. The soft tissues of the neck are then separated allowing for the disc to be removed. Anterior cervical discectomy has proven to be a safe and effective procedure for the treatment of degenerative disc disease. The anterior approach allows direct visualization of the entire interspace and wide decompression of the anterior aspect cervical spinal cord and nerve roots. It may be undertaken in cases of multilevel disease and interbody fusion may be performed if required
Study NCT06648941 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Muscle release
Description: supraspinatus muscle release
Study NCT06117709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-STAMP
Description: A patient-facing smartphone application that hosts participants' analgesic and laxative medications, provides pain-specific psychoeducation, collects patient reported outcomes, and provides feedback to participant symptoms.
Study NCT05477212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: all patients will receive a very low calorie ketogenic diet
Study NCT06485349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Leaf Extract (OLE)
Description: Daily dose of 750mg OLE consumed with water after breakfast without any modification of their dietary patterns for 90 days.
Study NCT06485349 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg microcrystalline cellulose
Study NCT05617638 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Participants will watch nature images in virtual reality from the e-Natureza VR Database for 20 minutes for 2 consecutive days.
Study NCT05333939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa leaf powder
Description: capsule ingestion
Study NCT05333939 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule ingestion
Study NCT06566209 — intervention group
Intervention type: DEVICE
Intervention: Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET)
Description: Receive 18F-FDG PET/CT
Study NCT06060613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OBX-115
Description: A tumor sample is obtained from each participant for autologous OBX-115 manufacture.~After lymphodepletion including cyclophosphamide and fludarabine, participant will receive OBX-115 infusion, followed by a short course of acetazolamide.
Study NCT04087629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataCTX® gel
Description: Gel forming flexible wound dressing for the prevention and treatment of radiation dermatitis
Study NCT05142150 — intervention group
Intervention type: OTHER
Intervention: Questionaire
Description: Patient questionaires collecting data on quality of life, illness management, communication and decision making. Patient report data of end of life care ( i.e administration of chemotherapy, surgical interventions, palliative care involvement, hospital admissions) through as self reported diary.~Carer for patients questionnaires their satisfaction with care. 5-7 weeks after patient deceased carer completes bereavement questionnaire and quality of death and dying.
Study NCT05972291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Glutamine
Description: You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 12 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
Study NCT05972291 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Arm
Description: You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 12 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
Study NCT05356962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StOP?-protocol
Description: The StOP?-protocol is an intra-operative briefing initiated by the responsible surgeon. When performing a StOP?-protocol, the surgeons inform the team present in the operating room about the Status (St) of the operation, the Objectives (O) of the operations, the potential problems (P) they may meet and encourage the team to ask questions or voice concerns (?). The responsible surgeon announces at the team timeout when they plan to perform the StOP-protocol(s).
Study NCT05619536 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD388 Injection
Description: CD388 liquid for injection
Study NCT05619536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Sterile normal saline for injection
Study NCT05666414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sandwich interpositional bone grafting computer guided
Description: performing the 2 vertical and the 1 horizontal osteotomies using a cutting patient specific guide and fixation of the vertically elevated bony segment after gap calculation using patient specific fixation guides
Study NCT05666414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional interpositional bone grafting
Description: performing the conventional interpositional sandwich osteotomies free-hand and fixation of the mobilized bone segment free-hand
Study NCT05314140 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary artery calcium score evaluation
Description: The evaluation of the coronary artery calcium score will be performed with chest CT scan
Study NCT05284292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GUARDIAN platform
Description: The enrolled elderly subjects and their caregivers will use at home the GUARDIAN platform consists of the Senior App, the Caregiver App and the Misty II robot.
Study NCT05714046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: An informative presentation
Study NCT05714046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga training
Description: Yoga exercise training
Study NCT05289375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vacucis autovaccine
Description: A sample will be taken from all participants in group T following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory. After 1 month from the sample collection, the laboratory will send in a container/dispenser (with the same appearance in both groups) to the T group will be administered the complete autovaccine ((with two applications per day for 7 weeks)
Study NCT05616117 — intervention group
Intervention type: OTHER
Intervention: Intrauterine 90µg D-vitamin
Description: Children of mothers who received 90 µg vitamin D3 daily during pregnancy:10 µg from a standard prenatal multivitamin + an additional supplement containing 80µg of vitamin D3
Study NCT05616117 — intervention group
Intervention type: OTHER
Intervention: Intrauterine 10µg D-vitamin
Description: Children of mothers who received 10 µg vitamin D3 daily during pregnancy, which is the dose in a standard prenatal multivitamin and the dose currently recommended by the Danish Health Authorities to all pregnant women. They will receive a prenatal vitamin containing 10µg of vitamin D + a placebo supplement.
Study NCT05525988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemi-Hamate Transfer for Proximal Pole Scaphoid Reconstruction
Description: Surgical Technique:~The participants will be positioned in the supine decubitus on the surgical table with the operated upper limb put on a C-arm (Mobile fluoroscopy device) compatible surgical arm-board. After anesthesia, a pneumatic tourniquet will be placed with a cuff pressure raised to 250 mmHg, then the limb is draped in the regular sterile fashion. Through a dorsal approach to the wrist joint, the proximal pole of scaphoid bone will be assessed before resectioning for confirmation that it cannot be preserved. The hamate bone will be exposed through capsulotomy and the measurements of the resected scaphoid will be transferred. The harvested H-H autograft will be placed and fixed to the distal scaphoid segment. Wound closure is then performed in layers in the usual fashion, and the wound will be covered by a sterile gauze, then a short-arm thumb spica splint will be put on.
Study NCT05012904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent involvement application
Description: A parent was involved in the procedure. The parent held the children in their arms and holding the extremity from which the blood was drawn, holding the hands of children and communicating with their children in the child's room, and in this way the parent was involved in the procedure.
Study NCT06299904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Air-pulse Stimulation
Description: Connected the oxygen humidification bottle to a fibreoptic endoscope, then inserted the terminal into the nasal cavity and the pulse sensation stimulation generated by oxygen was transmitted through the internal port of the fibreoptic endoscope to the anterior wall of the pyriform recess or to the folds of the arytenoepiglottis. (5 min once a day for 2 weeks)
Study NCT06299904 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Conventional air-pulse stimulation
Description: The terminal airway of the air pulse was placed in the oral cavity, specifically in the patient's palatoglossal arch, pharyngeal posterior wall, tongue base, and other areas. The airbag was quickly squeezed to generate airflow and stimulate the mucosa.(5 min once a day for 2 weeks)
Study NCT05203549 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor biopsy
Description: Patients with gastric cancer will undergo tumor biopsy before receiving neoadjuvant therapy, conversion therapy, or palliative therapy
Study NCT02815124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Standard of Care
Study NCT02815124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Image-Guided Cochlear Implant Programming
Description: Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Image-Guided Cochlear Implant Programming
Study NCT05289375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A sample will be taken from all participants in group P following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory (as in group T). After 1 month from the collection of the sample, the laboratory will send it in a container/dispenser (with the same appearance in both groups). The content in group P will receive a placebo in the same dosage and temporality as group T, it will be the same except for the active ingredient, that is, only thimerosal, methylcellulose, sodium chloride and orange essence.
Study NCT05999513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casdatifan
Description: Administered as specified in the treatment arm
Study NCT05431946 — intervention group
Intervention type: BEHAVIORAL
Intervention: Advance Care Planning and the consequent actions
Description: The palliative care intervention is based on the advance care planning process and the actions taken as a consequence of these conversations. The goal is the identification, assessment, and treatment of physical, psychosocial, or spiritual symptoms and problems.~Advance care actions~These are the actions taken to fulfill the advance care plan and can include, but are not limited to:~treatments: pharmacological, psychosocial (priest, psychologist, etc.) referrals: rehabilitation, specialized palliative care team, hospice, etc. communication initiatives with relatives, primary care, public authorities
Study NCT06158568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous Electrical Nerve Stimulation
Description: Application of a electrical current percutaneously (at the motor response intensity) targeting the suprascapular and axillar nerves
Study NCT06158568 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Percutaneous Electrical Nerve Stimulation
Description: Application of sham electrical current (no intensity) percutaneously targeting the suprascapular and axillar nerves
Study NCT06158568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Application of three weeks of progressive exercises targeting the shoulder musculature
Study NCT06158568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Application of three weeks of progressive exercises targeting the shoulder musculature
Study NCT06158568 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Application of three weeks of progressive exercises targeting the shoulder musculature
Study NCT06559189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19x22 CAR T
Description: The CD19 CAR contains an FMC63 binding domain, a CD28 hinge/transmembrane/endodomain, and a CD3 zeta endodomain. The CD22 CAR contains the binding domain (m971), a CD8alpha hinge and transmembrane domain, a 41BB endodomain, and a CD3 zeta endodomain.
Study NCT05622045 — intervention group
Intervention type: BEHAVIORAL
Intervention: Voice data
Description: Recorded response to a question about their participation in a weight loss study.
Study NCT06430502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Treatment Vaccine; PD-1/L1 inhibitors
Description: Before and after the patient's treatment period using PD-1 inhibitors，patients will receive tumor treatment vaccine(TTV), which would be given deep subcutaneously in the arm or near the tumor.The initial dose is 1ml each time, if the reaction isn't obvious, the dose can be appropriately increased to 2.5-4.0ml each time.The interval between injections can be shortened or extended depending on the patient's condition and response.
Study NCT05270317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Graft Cultivation and Harvesting
Description: Participants will be randomly assigned preoperatively into three surgical groups depending on cultivation time: early-stage group, medium-stage group and late-stage group . Bone Graft Cultivation is a two-stage procedure aiming at generating new bone tissue for grafting by periosteal elevation . The first stage is the insertion of space-occupying implant which is responsible for keeping periosteal elevation for a defined time to stimulate new bone formation. The second stage is the extraction of woven bone that has been formed together with the implant.
Study NCT05325658 — intervention group
Intervention type: OTHER
Intervention: FEES, treatment with modified diet, electrical swallowing muscle stimulation.
Description: Endoscopic swallowing assessment (FEES) consists of three parts:1) assessment of mouth, throat anatomy and more; 2) the patient is given to swallow a certain amount and consistency of liquids and solid food. 3) evaluated: preparation of the bolus for swallowing, aspiration. An 8-point Penetration-Aspiration scale is described.Swallowing exercises. Swallowing exercises are also used in practice, which can help coordinate the swallowing muscles or stimulate the nerves involved in the swallowing reflex.Transcutaneous electrical stimulation is a method of treating dysphagia in which weak electrical impulses stimulate the muscles in the neck area associated with swallowing. In patients with oropharyngeal dysphagia, patients have great difficulty swallowing water of normal consistency or other non-thick liquids, so they should be thickened with special thickeners to such an extent that the patient does not experience discomfort and be able to swallow.
Study NCT05600036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: Oral tablet
Study NCT04611113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
Study NCT04611113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Nutritional Support
Description: In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement. The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
Study NCT05600036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study NCT05199909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib
Description: The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the researcher will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate.
Study NCT06276127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Bisoprolol
Description: Participants in this group will receive a single oral dose of Bisoprolol, set at a dosage of 5 mg, with a maximum dose limit of 5 mg.
Study NCT06276127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Diltiazem
Description: Participants in this group will be administered a single intravenous dose of diltiazem at a dosage of 0.25 mg/kg, with a maximum dose capped at 30 mg.
Study NCT06420674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders is a psychological intervention that focuses on a wide range of emotional disorders (i.e., anxiety, depression and related disorders). It allows care for comorbid disorders, subclinical or unspecified symptoms reducing associated costs and improving response to treatment.~In our study, the Unified Protocol preventive program will be applied throughout 10 online modules. Women will have access to a web-page (moodle version) that includes audiovisual materials (e.g., written manual, videos, editable registers) and psychological assessments.
Study NCT05439577 — intervention group
Intervention type: DRUG
Intervention: Mucopolysaccharide Polysulfate Cream
Description: Patients using Hirudoid® alone
Study NCT05439577 — intervention group
Intervention type: DRUG
Intervention: Mucopolysaccharide Polysulfate Cream and glucocorticoids
Description: Patients using Hirudoid® and glucocorticoids (Combination therapy, but not always)
Study NCT04519541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Thermal Ablation of the Medial Branch Nerves using the Neurolyser XR
Description: Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
Study NCT05709444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bremelanotide
Description: Bremelanotide is a cyclic, heptapeptide analog of the endogenous peptide alpha melanocortin stimulating hormone (αMSH).
Study NCT05709444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAAS inhibition therapy
Description: RAS-acting agents are medicines acting on a hormone system that helps to control blood pressure and the amount of fluid in the body.
Study NCT06000501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serdexmethylphenidate/dexmethylphenidate
Description: Azstarys capsules for once-daily oral use for three weeks. Flexible dose starting at 39.2 mg serd-mph/7.8 mg d-mph and moving up to 52.3 mg serd-mph/10.4 mg d-mph.
Study NCT05148403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glibenclamide
Description: Glibenclamide was given orally or by nasal feeding
Study NCT06463483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic 780G System
Description: Automated insulin delivery using Medtronic 780G system
Study NCT06463483 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitoring
Description: Usual care with continuous glucose monitoring
Study NCT06605430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Cannabis
Description: The Early Cannabis group will be provided with 8 weeks of medical cannabis at no charge. Following 8 weeks of cannabis, the Early Cannabis group will be observed as per standard of care for the remaining 8 weeks. The Delayed Cannabis group will receive usual care for the first 8 weeks, and then be provided up to 8 weeks of medical cannabis at no charge for the second 8 weeks. Prior to receiving cannabis, patients must first be certified by a provider for eligibility to receive medical cannabis before registering with the Minnesota Medical Cannabis Program. Collective experience with precise dosage CBMs supports a pharmacist-guided titration protocol with robust patient input and close patient follow up. The treating pharmacist in the Minnesota Medical Cannabis Program thoroughly instructs patients on dose titration at the initial visit.